Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability.

STK33 kinase inhibitor BRD-8899 has no effect on KRAS-dependent cancer cell viability. Proc Natl Acad Sci U S A. 2012 Feb 21; 109(8):2860-5.

View in: PubMed

© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.